Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.01−0.98 (-5.45%)
Close on Nov 12, 2026Market cap $3.18BP/E –Yield –
Dyne Therapeutics cash
Cash and short-term investments held at the end of each period.
Dyne Therapeutics's cash was $1.13B at Sep 30, 2026. For fiscal 2025 it was $1.11B, up 72.9% from the year before. The highest annual figure on record is $1.11B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | +72.9% |
| FY2024 | Dec 31, 2024 | $642.27M | +421.7% |
| FY2023 | Dec 31, 2023 | $123.10M | -51.9% |
| FY2022 | Dec 31, 2022 | $256.01M | -32.0% |
| FY2021 | Dec 31, 2021 | $376.57M | +9.1% |
| FY2020 | Dec 31, 2020 | $345.31M | +2260.0% |
| FY2019 | Dec 31, 2019 | $14.63M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.13B | +43.3% |
| Q2 FY2026 | Jun 30, 2026 | $898.48M | +31.4% |
| Q1 FY2026 | Mar 31, 2026 | $972.16M | +43.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.11B | +72.9% |
| Q3 FY2025 | Sep 30, 2025 | $791.89M | +9.4% |
| Q2 FY2025 | Jun 30, 2025 | $683.93M | -12.2% |
| Q1 FY2025 | Mar 31, 2025 | $677.49M | +49.4% |
| Q4 FY2024 | Dec 31, 2024 | $642.27M | +421.7% |
| Q3 FY2024 | Sep 30, 2024 | $723.67M | +358.5% |
| Q2 FY2024 | Jun 30, 2024 | $778.84M | +274.9% |
| Q1 FY2024 | Mar 31, 2024 | $453.55M | +90.4% |
| Q4 FY2023 | Dec 31, 2023 | $123.10M | -51.9% |
| Q3 FY2023 | Sep 30, 2023 | $157.82M | -36.4% |
| Q2 FY2023 | Jun 30, 2023 | $207.73M | -28.8% |
| Q1 FY2023 | Mar 31, 2023 | $238.21M | -26.3% |
| Q4 FY2022 | Dec 31, 2022 | $256.01M | -32.0% |
| Q3 FY2022 | Sep 30, 2022 | $248.14M | -39.1% |
| Q2 FY2022 | Jun 30, 2022 | $291.84M | -33.0% |
| Q1 FY2022 | Mar 31, 2022 | $323.15M | -33.1% |
| Q4 FY2021 | Dec 31, 2021 | $376.57M | +9.1% |
| Q3 FY2021 | Sep 30, 2021 | $407.52M | +7.4% |
| Q2 FY2021 | Jun 30, 2021 | $435.59M | +2877.0% |
| Q1 FY2021 | Mar 31, 2021 | $483.09M | – |
| Q4 FY2020 | Dec 31, 2020 | $345.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $379.61M | – |
| Q4 FY2019 | Dec 31, 2019 | $14.63M | – |
See a number that looks wrong?